Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour of variou...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Diabetol
Päätekijät: Schernthaner, Guntram, Shehadeh, Naim, Ametov, Alexander S., Bazarova, Anna V., Ebrahimi, Fahim, Fasching, Peter, Janež, Andrej, Kempler, Péter, Konrāde, Ilze, Lalić, Nebojša M., Mankovsky, Boris, Martinka, Emil, Rahelić, Dario, Serafinceanu, Cristian, Škrha, Jan, Tankova, Tsvetalina, Visockienė, Žydrūnė
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Commentary
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585305/
https://ncbi.nlm.nih.gov/pubmed/33097060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01154-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia